Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

British Journal of Cancer

Volumn 90, Issue 12, 2004, Pages 2317-2325

  O'Donnell, A ^a,b   Judson, I ^a,b   Dowsett, M ^c   Raynaud, F ^b   Dearnaley, D ^a,b   Mason, M ^d   Harland, S ^e   Robbins, A ^f   Halbert, G ^g   Nutley, B ^b   Jarman, M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Clinical study; Hormonal therapy; Pharmacokinetics; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; CB 7630; CYPROTERONE ACETATE; CYTOCHROME P450C17; ENZYME INHIBITOR; FLUTAMIDE; GOSERELIN; LEUPRORELIN; UNCLASSIFIED DRUG; 17 (3 PYRIDYL) 5,16 ANDROSTADIEN 3BETA ACETATE; 17-(3-PYRIDYL)-5,16-ANDROSTADIEN-3BETA-ACETATE; ANDROSTANE DERIVATIVE; LUTEINIZING HORMONE; TESTOSTERONE;

ABDOMINAL PAIN; ADRENAL CORTEX; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUSHING; GONAD FUNCTION; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MALE; MULTIPLE DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS; BIOSYNTHESIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; SECRETION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANDROSTADIENES; CASTRATION; ENZYME INHIBITORS; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 3042784503     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601879     Document Type: Article

References (22)

1. 17α Inhibitors. J Steroid Biochem Mol Biol 60(5/6): 347-351
2. 17α (17α-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50(5/6): 267-273
3. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser T, Willi N, Mihatsch M, Sauter G, Kallioniemi O (1999) Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806
4. Cancer Research UK (2002) Combined statistics from Mortality Statistics Cause DH 2 Nat Stat (Eng & W), Registrar General for Scotland Annual Report, Registrar General for Nth Ire Annual Report May 2002
5. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16(7): 2557-2567
6. Denis L, Murphy GP (1993) Over view of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72: 3888-3895
7. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev 2: 389-396
8. Dowsett M, Shearer RJ, Ponder BA, Malone P, Jeffcoate SL (1988) The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. Br J Cancer 57(2): 190-192
9. Eichenberger T, Trachtenberg J (1988) Effects of high-dose ketoconazole in patients with androgenπindependent prostatic cancer. Am J Clin Oncol 11(Suppl 2):S104-S107
10. Gregory C, He B, Johnson RT, Ford H, Mohler JL, French FS, Wilson EM (2001a) Androgen receptor stabilisation in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61: 2892-2898
11. Gregory C, He B, Johnson RT, Ford H, Mohler JL, French FS, Wilson EM (2001b) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319
12. Griffin J, Wilson J (1998) Disorders of the testes and the male reproductive tract. In Williams Textbook of Endocrinology, Wilson J, Foster E, Kronenberg H and Larsen PR, et al (eds) pp 819-875. Philadelphia: WB Saunders Company
13. Harnett PR, Raghavan D, Caterson I, Pearson B, Watt H, Teriana N, Coates A, Coorey G (1987) Aminoglutethimide in advanced prostate cancer. Br J Urol 59(4): 323-327
14. Hellerstedt B, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52: 154-179
15. Linja M, Savinainen K, Saramaki O, Tammela T, Vessella R, Visakorpi T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555
16. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling Y-Z, Brodie A (2001) Cancer Res 60: 6630-6640
17. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D (1983) Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71(5): 1495-1499
18. Oh WK (2002) Secondary hormonal therapies in the treatment of prostate cancer. Urology 60(Suppl 3): 87-92
19. 17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 38: 2463-2471
20. Rostom AY, Folkes A, Lord C, Notley RG, Schweitzer FA, White WF (1982) Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol 54(5): 552-555
21. Rowlands MG, Barrie SE, Chan F, Houghton J, Jarman M, McCague R, Potter GA (1995) Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P450-17alpha) with resistance to esterase hydrolysis. J Med Chem 38(21): 4191-4197
22. Schwimmer B, Parker B (1996) Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors or the synthesis and actions of adrenocortical hormones. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Gilman AG, Rall TW, et al (eds) pp 1459-1486. NewYork: Pergamon Press